NCT05584670 / 2022-001239-95: A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 285 | Europe, US, RoW | SAR445877, Cetuximab, Erbitux | Sanofi, Sanofi Aventis Recherche & Développement | Solid Tumor | 01/27 | 09/28 | | |